本文的目的是总结有关使用钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT-2i) 预防接受蒽环类药物治疗癌症的患者心脏毒性的数据。我们讨论了此类药物的潜在功效，结合了现有文献和正在进行的研究的见解。SGLT2i 是一类药物，最初是为治疗 2 型糖尿病而开发的，后来扩展到治疗射血分数降低和保留的心力衰竭，无论如何糖尿病状况。仍然需要有效且安全的治疗来预防接受蒽环类药物治疗的患者的心脏毒性。有人提出 SGLT2i 可以针对蒽环类药物的心脏毒性作用提供保护。一些提出的机制包括有益的代谢、神经激素和血流动力学效应、肾脏保护，以及减少炎症、氧化应激、细胞凋亡、线粒体功能障碍和离子稳态。来自基础科学和观察研究的新证据表明，SGLT2i 可能在预防化疗引起的心脏毒性方面发挥作用。需要进行随机对照试验来最终确定 SGLT2 抑制剂作为心脏保护疗法对接受蒽环类药物治疗癌症的患者的作用。© 2024。作者。

The goal of this paper is to summarize the data pertaining to the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) for the prevention of cardiotoxicity in patients receiving anthracyclines for cancer treatment. We discuss the potential efficacy of this class of medications, incorporating insights from existing literature and ongoing studies.SGLT2i are a class of medications which were initially developed for treatment of Type 2 diabetes and later extended to treat heart failure with reduced and preserved ejection fraction regardless of diabetes status. There remains a need for effective and safe treatments to preventing cardiotoxicity in anthracycline-treated patients. It has been proposed that SGLT2i may provide protection against the cardiotoxic effects of anthracyclines. Some of the proposed mechanisms include beneficial metabolic, neurohormonal, and hemodynamic effects, renal protection, as well as a decrease in inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ion homeostasis. There is emerging evidence from basic science and observational studies that SGLT2i may play a role in the prevention of chemotherapy-induced cardiotoxicity. Randomized controlled trials are needed to conclusively determine the role of SGLT2 inhibitors as a cardioprotective therapy in patients receiving anthracyclines for the treatment of cancer.© 2024. The Author(s).